News
Dec 10, 2023 06:15 ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sportradar Group AG - SRAD
NEW YORK, Dec. 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sportradar Group AG ("Sportradar" or the "Company") (NASDAQ: SRAD). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Dec 10, 2023 06:00 ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adobe, Inc. - ADBE
NEW YORK, Dec. 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Adobe, Inc. ("Adobe" or the "Company") (NASDAQ: ADBE). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Dec 10, 2023 04:00 ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Illumina, Inc. - ILMN
NEW YORK, Dec. 10, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Illumina, Inc. ("Illumina" or the "Company") (NASDAQ: ILMN). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Dec 10, 2023 01:00 ET
Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced positive final results from the Phase 2 TELLOMAK study in Sézary Syndrome (SS). The results were presented at the ASH 2023 Annual Meeting, in San Diego, California.
Dec 09, 2023 20:31 ET
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced a poster presentation at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition...
Dec 09, 2023 20:30 ET
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
Pooled analysis of the FELIX Phase Ib/II study demonstrated prolonged event free survival and low overall immunotoxicity across all cohorts in r/r B-ALL, and particularly in patients with low leukemic burden at lymphodepletionLonger-term data from a...
Dec 09, 2023 19:45 ET
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Li-Cycle Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – LICY
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Li-Cycle Holdings Corp. (NYSE: LICY) between June 14, 2022 and October 23, 2023, both dates inclusive (the “Class Period”), of the important January 8,...
Dec 09, 2023 19:00 ET
Agios Presents Positive Results from Phase 2 Portion of the RISE UP Pivotal Study in Sickle Cell Disease at 65th ASH Annual Meeting and Exposition
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today presented detailed results from the Phase 2 portion of the global RISE UP study of mitapivat in sickle cell...
Dec 09, 2023 19:00 ET
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
Pfizer Inc. (NYSE: PFE) today presented results from the pivotal Phase 3 BASIS clinical trial (
Dec 09, 2023 18:30 ET
Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting
Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced that a growing body of...
Dec 09, 2023 17:30 ET
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to treat and improve the lives of patients with genetically defined cancers and...
Dec 09, 2023 17:21 ET
ROSEN, LEADING INVESTOR COUNSEL, Encourages Expensify, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – EXFY
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Expensify, Inc. (NASDAQ: EXFY) pursuant and/or traceable to the Offering Documents issued in...
Dec 09, 2023 17:02 ET
FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meetin
FibroGen, Inc. (NASDAQ: FGEN) announced today the presentation of efficacy and safety data from MATTERHORN, a Phase 3 clinical study of roxadustat for the treatment of anemia in patients with lower risk transfusion-dependent myelodysplastic...
Dec 09, 2023 17:00 ET
Bristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Naïve Patients with Lower-Risk
Bristol Myers Squibb (NYSE: BMY) announced updated results from the primary analysis of the Phase 3 COMMANDS trial, comparing Reblozyl® (luspatercept-aamt) versus epoetin alfa for the treatment of anemia in erythropoiesis stimulating agent (ESA)-naïve patients with lower-risk myelodysplastic syndromes (MDS) (
Dec 09, 2023 15:04 ET
FTCH INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Farfetch Limited Investors with Substantial Losses Have Opportunity to Lead Case
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Farfetch Limited (NYSE: FTCH) securities between March 9, 2023 and August 17, 2023, all dates inclusive (the “Class Period”), have until December 19, 2023 to seek...
Dec 09, 2023 14:25 ET
LPSN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that LivePerson, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of LivePerson, Inc. (NASDAQ: LPSN) securities between May 10, 2022 and March 16, 2023, both dates inclusive (the “Class Period”), have until January 30, 2024 to seek appointment as lead plaintiff of the
Dec 09, 2023 13:30 ET
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today reported positive initial data from the Company’s ongoing Phase 2 SUMMIT trial evaluating...
Dec 09, 2023 13:15 ET
FSR INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Fisker Inc. Investors with Substantial Losses Have Opportunity to Lead Case
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Fisker Inc. (NYSE: FSR) securities between August 4, 2023 and November 20, 2023, both dates inclusive (the “Class Period”), have until January 26, 2024 to...
Dec 09, 2023 12:00 ET
Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of Hematology
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the presentation of data from a comprehensive safety review of...
Dec 09, 2023 12:00 ET
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced the presentation of initial...
Dec 09, 2023 12:00 ET
Corvus Pharmaceuticals Presents New Interim Soquelitinib Data from its Phase 1/1b T Cell Lymphoma Trial
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from its Phase 1/1b clinical trial of soquelitinib in patients with relapsed PTCL. Soquelitinib demonstrated durable...
Dec 09, 2023 12:00 ET
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demonstrated an overall response rate (ORR) of 82 percent, a complete response (CR)
Dec 09, 2023 12:00 ET
Rallybio Presents Natural History Study for Fetal and Neonatal Alloimmune Thrombocytopenia at the 65th American Society of Hematology Annual Meeting
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today presented details from the Rallybio Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT) natural history study in a poster presentatio
Dec 09, 2023 12:00 ET
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced a poster...
Dec 09, 2023 12:00 ET
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023
X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the presentation of additional preliminary data from its ongoing Phase 2 clinical trial evaluating the...
Dec 09, 2023 11:31 ET
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Reso
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or “bluebird”) today announced new and updated efficacy, safety and health-related quality of life (HRQoL) data from the Phase 1/2 HGB-206 Group C and Phase 3 HGB-210 studies of lovotibeglogene autotemcel (lovo-cel) gene therapy for sickle cell disease through five years of follow-up (median 35.5 months, range 0.3-61 months). Data were highlighted in a press briefing at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition and will be presented in an oral presentation on Monday, December 11, 2023 at 4:30 p.m. Paci
Dec 09, 2023 11:30 ET
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting
-- HARBOR Part 1 trial data in indolent systemic mastocytosis showed elenestinib was well-tolerated with broad symptom improvement, supporting further development to expand and extend company's SM franchise leadership --
Dec 09, 2023 11:30 ET
New Data Reinforce the Benefit of Early Preventative Treatment With Genentech’s Hemlibra (emicizumab-kxwh) for Babies With Severe hemophilia A
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab-kxwh) in previously untreated or minimally treated infants with severe hemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful bleed control in babies up to 12 months of age and was well tolerated. The new data were presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2023 in San Dieg
Dec 09, 2023 11:00 ET
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
- Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th American Society of Hematology (ASH) congress- Follicular lymphoma is the second most common form of non-Hodgkin's lymphoma
Dec 09, 2023 11:00 ET
New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL)
- Data from Phase 1/2 EPCORE™ NHL-1 study show patients treated with epcoritamab experienced 82% overall response rates (ORR) including 63% complete response (CR) rates as presented at the 65th American Society of Hematology (ASH) congress- Follicular lymphoma is the second most common form of non-Hodgkin's lymphoma
Dec 09, 2023 09:53 ET
NKLA FINAL DEADLINE ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Nikola Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – NKLA
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nikola Corporation (NASDAQ: NKLA) between February 24, 2022 and September 7, 2023, both dates inclusive (the “Class Period”), of the important December...
Dec 09, 2023 08:49 ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSTR, SRC, PATI, GRPH
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CapStar Financial Holdings, Inc....
Dec 09, 2023 08:49 ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSTR, SRC, PATI, GRPH
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CapStar Financial Holdings, Inc....
Dec 09, 2023 08:49 ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSTR, SRC, PATI, GRPH
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CapStar Financial Holdings, Inc....
Dec 09, 2023 08:49 ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CSTR, SRC, PATI, GRPH
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CapStar Financial Holdings, Inc....
Dec 09, 2023 08:42 ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HA, PFIN, IMGN, SP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hawaiian Holdings, Inc. (NASDAQ: HA)’s...
Dec 09, 2023 08:42 ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HA, PFIN, IMGN, SP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hawaiian Holdings, Inc. (NASDAQ: HA)’s...
Dec 09, 2023 08:42 ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HA, PFIN, IMGN, SP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hawaiian Holdings, Inc. (NASDAQ: HA)’s...
Dec 09, 2023 08:42 ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HA, PFIN, IMGN, SP
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Hawaiian Holdings, Inc. (NASDAQ: HA)’s...
Dec 09, 2023 08:30 ET
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data...
Dec 09, 2023 08:02 ET
MDRX INVESTOR ALERT: Kaplan Fox & Kilsheimer LLP Reminds Veradigm Investors of a Class Action Lawsuit and Upcoming Deadline
Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of purchasers of the common stock of Veradigm Inc. (“Veradigm” or the “Company”) (NASDAQ: MDRX), a healthcare technology company, between February 26, 2021 and...
Dec 09, 2023 05:55 ET
Completion of the Third Tranche of Stellantis Share Buyback Program and Weekly Report (December 1-7, 2023)
Completion of the Third Tranche of Stellantis Share Buyback Program and Weekly Report (December 1-7, 2023) AMSTERDAM, December 8, 2023 - Stellantis N.V. (“Stellantis” or the “Company”) announced today that its Third Tranche of the Share Buyback...
Dec 08, 2023 22:30 ET
BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s Warrants
VANCOUVER, BC / ACCESSWIRE / December 8, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) announces that, further to its news release dated November 24, 2023, it has settled an aggregate of $2,581,096 in convertible debentures and interest (the "Debt") owed to an arm's length creditor of the Company (the "Creditor"). In settlement of the Debt the Company issued the Creditor:
Dec 08, 2023 21:45 ET
ADAPTHEALTH SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Agains
NEW ORLEANS, Dec. 8, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until December 26, 2023 to file lead plaintiff applications in a securities class action lawsuit against AdaptHealth Corp. (NasdaqCM: AHCO), if they purchased or otherwise acquired the Company's shares (i) between August 4, 2020 and February 27, 2023, inclusive (the "Class Period"); and/or (ii) pursuant and/or traceable to the Company's January 2021 secondary public offering (the "SPO"). This action is pend
Dec 08, 2023 21:45 ET
BARCLAYS PLC SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Again
NEW ORLEANS, Dec. 8, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 2, 2024 to file lead plaintiff applications in a securities class action lawsuit against Barclays PLC (NYSE: BCS), if they purchased the Company's securities between July 22, 2019 and October 12, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Central District of California.
Dec 08, 2023 21:45 ET
CHARGEPOINT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Agains
NEW ORLEANS, Dec. 8, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 29, 2024 to file lead plaintiff applications in a securities class action lawsuit against ChargePoint Holdings, Inc. (NYSE: CHPT), if they purchased the Company's securities between June 1, 2023 and November 16, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of California.
Dec 08, 2023 21:45 ET
DOLLAR GENERAL SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuits Ag
NEW ORLEANS, Dec. 8, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 26, 2024 to file lead plaintiff applications in securities class action lawsuits against Dollar General Corporation (NYSE: DG), if they purchased the Company's securities between May 28, 2020 and August 31, 2023, inclusive (the "Class Period"). These actions are pending in the United States District Court for the Middle District of Tennessee.
Dec 08, 2023 21:45 ET
FISKER SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Fis
NEW ORLEANS, Dec. 8, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 26, 2024 to file lead plaintiff applications in a securities class action lawsuit against Fisker Inc. (NYSE: FSR), if they purchased or otherwise acquired the Company's securities between August 4, 2023 and November 20, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Central District of California.
Dec 08, 2023 21:45 ET
LIVEPERSON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against
NEW ORLEANS, Dec. 8, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 30, 2024 to file lead plaintiff applications in a securities class action lawsuit against LivePerson, Inc. (NasdaqGS: LPSN), if they purchased the Company's securities between May 10, 2022 and March 16, 2023, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
Dec 08, 2023 21:45 ET
ROBLOX SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF OVER $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Agains
NEW ORLEANS, Dec. 8, 2023 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 26, 2024 to file lead plaintiff applications in a securities class action lawsuit against Roblox Corporation (NYSE: RBLX), if they purchased or otherwise acquired the Company's shares between March 10, 2021 and February 15, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Southern District of New York.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2023 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.